Pawlikowska Ludmila, Poon K Y Trudy, Achrol Achal S, McCulloch Charles E, Ha Connie, Lum Kristen, Zaroff Jonathan G, Ko Nerissa U, Johnston S Claiborne, Sidney Stephen, Marchuk Douglas A, Lawton Michael T, Kwok Pui-Yan, Young William L
The Cardiovascular Research Institute, University of California, San Francisco 94110, USA.
Neurosurgery. 2006 May;58(5):838-43; discussion 838-43. doi: 10.1227/01.NEU.0000209605.18358.E5.
Patients with brain arteriovenous malformation (AVM) are at life-threatening risk of intracranial hemorrhage (ICH). Identification of genetic variants associated with increased new ICH risk would facilitate risk stratification and guide therapeutic intervention.
Brain AVM patients evaluated at University of California, San Francisco or Kaiser Permanente Northern California were followed longitudinally. Primary outcome was new ICH after diagnosis; censoring events were any AVM treatment or last follow-up examination. The association of ApoE epsilon2 and epsilon4 genotype with new ICH was evaluated by Kaplan-Meier survival analysis and further characterized via a Cox proportional hazards model.
We genotyped 284 brain AVM patients (50% women; 57% Caucasian; median follow-up time, 0.3 yr) including 18 patients with a history of new ICH). ApoE epsilon2, but not ApoE epsilon4 genotype, was associated with new ICH (P = 0.0052). ApoE epsilon2 carriers had fivefold increased risk of new ICH (hazard ratio, 5.09; 95% confidence interval, 1.46-17.7; P = 0.010; Cox proportional hazards model adjusting for race/ethnicity and clinical presentation). Subset analysis in the largest homogenous ethnic subcohort (Caucasians) confirmed the increased risk of new ICH in ApoE epsilon2 carriers (hazard ratio, 8.71; 95% confidence interval, 1.4-53.9; P = 0.020; multivariate model adjusting for clinical presentation).
ApoE genotype may influence the risk of ICH in the natural course of brain AVM. The identification of genetic predictors of ICH risk may facilitate estimation of AVM natural history risk and individualize clinical decision-making and therapeutic recommendations.
脑动静脉畸形(AVM)患者面临颅内出血(ICH)的生命威胁风险。识别与新发ICH风险增加相关的基因变异将有助于风险分层并指导治疗干预。
对在加利福尼亚大学旧金山分校或北加利福尼亚凯撒医疗集团接受评估的脑AVM患者进行纵向随访。主要结局是诊断后的新发ICH;截尾事件为任何AVM治疗或最后一次随访检查。通过Kaplan-Meier生存分析评估ApoE ε2和ε4基因型与新发ICH的关联,并通过Cox比例风险模型进一步进行特征分析。
我们对284例脑AVM患者(50%为女性;57%为白种人;中位随访时间为0.3年)进行了基因分型,其中包括18例有新发ICH病史的患者。ApoE ε2基因型而非ApoE ε4基因型与新发ICH相关(P = 0.0052)。ApoE ε2携带者发生新发ICH的风险增加了五倍(风险比,5.09;95%置信区间,1.46 - 17.7;P = 0.010;Cox比例风险模型校正种族/民族和临床表现)。在最大的同质种族亚组(白种人)中的亚组分析证实了ApoE ε2携带者新发ICH风险增加(风险比,8.71;95%置信区间,1.4 - 53.9;P = 0.020;校正临床表现的多变量模型)。
ApoE基因型可能在脑AVM的自然病程中影响ICH风险。识别ICH风险的基因预测因子可能有助于估计AVM的自然病史风险,并使临床决策和治疗建议个体化。